Smithkline Beecham Corporation

Glaxo Group Limited

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property Development Limited

Astex Therapeutics Limited

Other

Jeffrey Charles Boehm

Jerry Leroy Adams

Timothy Francis Gallagher

Ralph F Hall

James Francis Callahan

John J Taggart

Joseph Sisko

Xichen Lin

Qi Jin

Zehong Wan

Domingos J Silva

Jiri Kasparec

Irennegbe Kelly Osifo

Jeffrey K Kerns

Ravi Shanker Garigipati

Zhi-Qiang Peng

Paul E Bender

Alison Jo-Anne Woolford

Paul Bamborough

Thomas Daniel Heightman

Anthony William James Cooper

Peter William Sheldrake

Dennis Lee

Hongxing Yan

John C Lee

Beth Adams Norton

Stefano Livia

Neysa Nevins

Katherine L Widdowson

Charlotte Mary Griffiths-Jones

Don Edgar Griswold

David C Underwood

Michael J Bower

Tindy Li

Zhi Qiang Peng

Sidney M Hecht

Gordon Saxty

Randall K Johnson

Margaret E Sorenson

Christopher E Neipp

David Norton

Nicole Cathleen Goodwin

Susan Mary Thompson

Jakob Busch-Petersen

William D Kingsbury

Yun Jin

Ami Lakdawala Shah

Thomas Glanmor Davies

Guoliang Lin

Hendrika Maria Gerarda Willems

Ravishanker Garigipati

Roderick S Davis

Wei Fu

Huijie Li

Kenneth G Holden

Paris L Hamilton

Hendrika Maria Willems

Beth A Norton

Provided are aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

Nrf2 regulators

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

NRF2 regulators

Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

7,8-dihydropyrido[2,3-d]pyrimidin-4-yl substituted compounds as inhibitors of p38 kinase

The present invention is directed to novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds, compositions, and use in therapy as CSBP/RK/p38 kinase inhibitors of Formulas (V) and (Va) wherein inter alia,

Compounds

The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK&#x3b2;) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Indole carboxamides as IKK2 inhibitors

Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy

2,4,5-Trisubstituted pyrimidine compounds

Novel substituted pyrimido[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use use in therapy as CSBP/RK/p38 kinase inhibitors.

Tetrasubstituted pyrimidine compounds as chemical intermediates

Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.

The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein wherein

[object Object]

This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N&#x2033;-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.

Growing community of inventors

King of Prussia, PA, United States of America

Jeffrey Charles Boehm